Celgene (CELG) option implied volatility decreases on Bristol-Myers (BMY) acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Leerink Partners Downgrades Celgene (CELG) to Market Perform Following Acquisition
January 3, 2019 11:56 AM ESTLeerink Partners analyst Geoffrey Porges downgraded Celgene (NASDAQ: CELG) from Outperform to Market Perform with a price target of $102.00 (from $112.00) following acquisition.
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $66.64 yesterday.
... More